Loading stock data…
BioVie Inc (BIVI)
$2.07+0.07 (+3.50%)
Market ClosedLast close Sep 8
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioVie Inc. in the Healthcare sector is trading at $2.07 with a market capitalization of $12M. Wall Street consensus targets $5.25 (2 analysts), implying a +153.9% move over the next 12 months. The stock is currently 45% below its 52-week high of $3.79, remaining 38.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +153.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.39M↑ | -$6.26M↓ | -$5.28M↓ | -$3.66M↓ | -$2.99M |
| Net Income | -$5.27M↑ | -$6.07M↓ | -$5.09M↓ | -$3.49M↓ | -$2.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-127.61%
Volume
Today's trading volume
318,488
Recent News
Dow closes sharply lower as oil surge fuels inflation fears
An escalating US-Canada trade dispute added to inflation concerns at the start of the holiday-shortened week
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson’s disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson’s disease...
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based...
Parkinson's drug developers are betting big on inflammation
For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease. That bet hasn't paid off yet. Now a growing slice of the industry is chasing a different culprit: inflammation in the brain...
BioVie stock sinks on Phase IIb Parkinson’s trial data
BioVie used an endpoint called EPNIC-15, which is not well known and only appears to be referenced in papers by the company itself.